Human Pharmacokinetics and Pharmacodynamics of MF 701 Dermatan Sulfate Administered by Continuous Intravenous Infusion

Summary

The pharmacokinetics and haemostatic effects of MF 701 dermatan sulfate (DS) administered by i. v. infusion were studied in 11 healthy volunteers. Each subject received 0.6 mg kg^-1 h^-1 MF 701 for 10 h. DS plasma concentrations were measured by a chromogenic assay based on the catalysis of thrombin inhibition by HCII. DS plasma levels followed a single compartment pharmacokinetic model, with a half-life of 1.28 ± 0.46 h, a plasma clearance of 2.75 ± 0.46 1/h and a volume of distribution of 4.92 ± 1.36 1 (means ± SD). Steady-state was reached 3 to 6 h after infusion started. The maximal DS plasma concentration was 16.4 ± 5.7 μg/ml. Maximal APTT prolongation over pre-infusion values was 42 ± 7%; TCT performed with bovine and human thrombin was prolonged by 16 ± 7% and 83 ± 35% respectively. No anti-IIa or anti-Xa activities were detected by chromogenic tests. The treatment was well tolerated. The pharmacokinetics of MF 701 infusion are consistent with those previously described after i. v. bolus administration. The infusion of MF 701 allows fast achievement and steady maintenance of elevated DS plasma concentrations.

• References

• 1 Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 2 Toulon P, Aiach M, Gianese F. In vitro study of a new potential antithrombotic drug MF 701 (dermatan sulfate). In: Heparin and Related Polysaccharides Ofosu FA. et al (eds) Ann NY Acad Sci; 1989. 556 486-488
• 3 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1989; 64: 309-317
• 4 Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemostas 1989; 61: 7-9
• 5 Maggi A, Abbadini N, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-335
• 6 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
• 7 Soldani G, Mengozzi G, Gianese F. Dermatan sulfate prevents carrageenin-induced tail thrombosis in the rat. In: Xth International Congress on Thrombosis: The Mediterranean League against Thromboembolic Diseases Athens: 05/1988. Abstract Book, p 73
• 8 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. Effects of dermatan sulfate and heparin on inhibition of thrombus growth “in vivo”. In: Heparin and Related Polysaccharides Ofosu FA. et al (eds) Ann NY Acad Sci; 1989. 556 304-312
• 9 Okwusidi J, Falcone M, Van Ryn McKenna J, Hirsh J, Ofosu FA, Buchanan MR. “In vivo” catalysis of thrombin inhibition by antithrombin III or heparin cofactor II and antithrombotic effect: differential effects of unfractionated heparin and dermatan sulfate. Thromb Haemorrh Disorders 1990; 1: 77-80
• 10 Dawes J, Hodson BA, McGregor IR, Pepper DS, Prowse CV. Pharmacokinetics and biological activities of dermatan sulfate (Mediolanum MF 701) in healthy human volunteers. In: Heparin and Related Polysaccharides Ofosu FA. et al. (eds) Ann NY Acad Sci; 1989. 556 292-303
• 11 Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulfate administered to man. Studies using a radioiodinated derivative. Thromb Haemostas 1989; 62: 945-949
• 12 Dawes J, Forbes C, Belch J, McLaren M, Lane D, Bray B. Human pharmacokinetics of MF 701 dermatan sulfate. Thromb Haemostas 1989 62. 433 (Abstr)
• 13 Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, Sié P, Boneu B. Pharmacokinetics and pharmacodynamics of dermatan sulfate in man. Blood 1989; 74: 1577-1582
• 14 Gianese F, Lucchelli PE. A survey of the clinical experience with dermatan sulfate. Semin Thromb Hemostas 1991 (in press)
• 15 Dupouy D, Sié P, Dol F, Boneu B. A simple method to measure dermatan sulfate at submicrogram concentrations in plasma. Thromb Haemostas 1988; 60: 236-239
• 16 Proctor RR, Rapaport SI. The PTT with kaolin. Am J Clin Pathol 1961; 33: 212-219
• 17 Teien AN, Lie M, Abilgaard V. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
• 18 Powell MJ D. A method for minimizing a sum of squares of non-linear functions without calculating derivatives. Comput J 1965; 7: 303-307
• 19 Buff aloe GW, Heineken FG. Plasma volume nomograms for use in therapeutic plasma exchange. Transfusion 1983; 23: 355-357
• 20 Rowland M, Tozer T. Clinical Pharmacokinetics. Lea & Febiger; Philadelphia, PA: 1981
• 21 Pratt CW, Whinna HC, Meade JB, Treanor RE, Church FC. Physicochemical aspects of heparin cofactor II. In: Heparin and Related Polysaccharides Ofosu FA. et al. (eds) Ann NY. Acad Sci; 1989. 556 104-115
• 22 Denson KW E. The sensitivity of human and bovine thrombin to heparin in plasma. Thromb Res 1981; 23: 207-213